Covance Recognized with Frost & Sullivan Asia Pacific CRO Customer Value Leadership Award

BURLINGTON, N.C. --(BUSINESS WIRE)--Oct. 16, 2017-- LabCorp (NYSE: LH), a leading global life sciences company, announced today that its Covance Drug Development business (Covance) has been awarded the 2017 Frost & Sullivan Asia Pacific CRO Customer Value Leadership Award.

Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021

BURLINGTON, N.C. --(BUSINESS WIRE)--Oct. 2, 2017-- LabCorp® (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below. The Zero Coupon Notes are convertible into cash and Common Stock of LabCorp, if any, subject

LabCorp Objects to Proposed PAMA 2018 Medicare Payment Rates for Clinical Laboratory Tests; Calls for Delay in Implementation to Avoid Significant Harm to Medicare Beneficiaries

BURLINGTON, N.C. --(BUSINESS WIRE)--Sep. 25, 2017-- LabCorp (NYSE: LH), a leading global life sciences company, today issued the following response to the Sept. 22 publication by the Centers for Medicare and Medicaid Services (CMS) of proposed 2018 Medicare reimbursement rates for clinical

LabCorp Presents Nine Studies, Including Novel Research on Improving Genetic Counseling Quality, at the National Society of Genetic Counselors Annual Conference

LabCorp’s Integrated Genetics Specialty Laboratory Leverages Decades of Experience in Genetics Research and Practice to Improve Health and Improve Lives BURLINGTON, N.C. --(BUSINESS WIRE)--Sep. 14, 2017-- LabCorp (NYSE: LH), a leading global life sciences company, announced today that Integrated

LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest

BURLINGTON, N.C. --(BUSINESS WIRE)--Sep. 11, 2017-- LabCorp® (NYSE: LH) announced today that for the period of September 11, 2017 to March 9, 2018 , its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) will, subject to the terms of the Zero Coupon Notes, accrue contingent

LabCorp Named Among “The World’s Most Innovative Companies” in Forbes’ 2017 Ranking

BURLINGTON, N.C. --(BUSINESS WIRE)--Sep. 7, 2017-- LabCorp® (NYSE: LH), a leading global life sciences company, has been named to Forbes’ 2017 ranking of “The World’s Most Innovative Companies.” “Innovation in guiding patient care is what we do at LabCorp, so being recognized as one of the world’s

LabCorp is Scheduled to Present at the Morgan Stanley Global Healthcare Conference

BURLINGTON, N.C. --(BUSINESS WIRE)--Sep. 5, 2017-- LabCorp® (NYSE:LH) today announced it will participate at the Morgan Stanley Global Healthcare Conference . LabCorp’s presentation is planned for Tuesday, September 12, 2017 , at 8:35 am (ET) . A live audio webcast will be available via the Company

LabCorp Completes Acquisition of Chiltern

Strengthens LabCorp’s Position as a Global Life Sciences Company with Leading Diagnostics and Drug Development Businesses BURLINGTON, N.C. --(BUSINESS WIRE)--Sep. 1, 2017-- LabCorp® (NYSE: LH), a leading global life sciences company, has completed its previously announced acquisition of Chiltern,

LabCorp’s Acquisition of Chiltern Clears Antitrust Review

BURLINGTON, N.C. --(BUSINESS WIRE)--Aug. 24, 2017-- LabCorp® (NYSE: LH), a leading global life sciences company, announced today that the Federal Trade Commission had granted its request for early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or

LabCorp Names Nationally Recognized Health-Policy Expert Dr. Brian Caveney As Enterprise-Wide Chief Medical Officer

Caveney is an Influential Thought Leader in Healthcare Financing, Regulatory Initiatives and Value-Based Care Models BURLINGTON, N.C. --(BUSINESS WIRE)--Aug. 24, 2017-- LabCorp® (NYSE: LH), a leading global life sciences company, announced today that Dr.